Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Closed Solicitation Posted
- Solicitation number
- HT9402-24-Q-9205
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- San Antonio, Texas 78230, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Defense (DoD) is seeking to establish Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program Agreements (UF ADP) for pharmaceutical agents through a Request for Quotation (RFQ). The RFQ solicits quotes from manufacturers for newly approved drugs in the Gastrointestinal-1 Agents and Targeted Immunomodulatory Biologics - Tumor Necrosis Factor Inhibitors therapeutic classes. Quotes are due by April 12, 2024, for consideration at the May 2024 DoD Pharmacy and Therapeutics (P&T) Committee meeting. The DoD may award the UF BPA and UF ADP agreements based on the P&T Committee's formulary decisions. Manufacturers must submit responses to clinical evaluation questions and fully executed signature pages along with their quotes.
There is no set-aside designation for this opportunity. The NAICS code is likely 325412 (Pharmaceutical Preparation Manufacturing) and the PSC code is likely 6505 (Drugs and Biologicals). The DoD is the sole agency involved, and the place of performance is San Antonio, TX. The contract value or budget range is not explicitly stated, but the RFQ is seeking quotes for newly approved drugs to be included in the DoD's Uniform Formulary.
Notice text
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: May 2024: The following newly approved drugs will be reviewed:
a. Eohilia – Gastrointestinal-1 AGENTS - Subclass: Gastrointestinal Steriods
b. Zymfentra - Targeted Immunomodulatory Biologics – Subclass: Tumor Necrosis Factor Inhibitors
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-24-Q-9205.
Pre-quotation teleconference is on April 3, 2024, details are stated in Part 2.5. Pre-quotation teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.
Files
| File | Type | Posted |
|---|---|---|
| NAD RFQ3 - Eohilia - GAST-1 AGENTS - GAST STEROIDS.xlsx | XLSX spreadsheet | |
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| Price Appendix FAQ NAD.pdf | ||
| RFQ HT9402-24-Q-9205 NAD.pdf | ||
| NAD RFQ3 - Zymfentra - TIB - Tumor Necrosis Factor Inhibitors.xlsx | XLSX spreadsheet |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 6505--Request for Information (RFI) - Specialty Pharmacy – Pharmaceutical Prime Vendor (PPV) 2028 | Department of Veterans Affairs | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity